Small-scale Manufacturer AiPing Pharmaceutical is a US-based generic pharmaceuticalmanufacturer with a very small employee base (2-10), suggesting agility but limited internal capacity. This indicates potential partnership opportunities to handle scale-up support, contract manufacturing, or white-label collaborations to expand product reach without incurring significant internal overhead.

Asset Reallocation Recent news indicates AiPing sold assets to Shandong Xinhua Pharma and had ibuprofen ANDA assets in the US transferred in 2018. This points to a potential opportunity to discuss asset acquisition, licensing, or co-development of other generic/OTC products to optimize portfolio value.

Generic Focus AiPing specializes in generic prescription and OTC products in oral solid dose forms. This presents a sales angle around expanding into additional generic lines, accelerated approvals for new formulations, or distribution partnerships to broaden product availability in the US market.

Revenue Range With estimated revenue between $10M and $25M, AiPing sits in a size bracket that often seeks strategic partnerships to accelerate growth, reduce time-to-market, and leverage global distribution networks for scale while managing risk.

Tech & Compliance The tech stack includes common web and security technologies, suggesting potential for standardized digital collaboration, e-procurement, and secure data exchange. Propose integrated supply chain platforms, regulatory documentation support, and streamlined compliance workflows to simplify joint ventures.